Literature summary for 1.5.3.13 extracted from

Basu, H.S.; Thompson, T.A.; Church, D.R.; Clower, C.C.; Mehraein-Ghomi, F.; Amlong, C.A.; Martin, C.T.; Woster, P.M.; Lindstrom, M.J.; Wilding, G.
A small molecule polyamine oxidase inhibitor blocks androgen-induced oxidative stress and delays prostate cancer progression in the transgenic adenocarcinoma of the mouse prostate model (2009), Cancer Res., 69, 7689-7695.

Search for more literature for 1.5.3.13

Application

Application	Comment	Organism
pharmacology	N,N'-butanedienyl butanediamine, i.e. MDL 72527 or CPC-200, a small molecule specific inhibitor of polyamine oxidase, effectively blocks androgen-induced reactive oxygen species production in human prostate cancer cells, as well as significantly delays prostate cancer progression and death in animals developing spontaneous prostate cancer	Homo sapiens

Inhibitors

Inhibitors	Comment	Organism	Structure
N,N'-butanedienyl butanediamine	i.e. MDL 72527 or CPC-200, a small molecule specific inhibitor of polyamine oxidase, effectively blocks androgen-induced reactive oxygen species production in human prostate cancer cells, as well as significantly delays prostate cancer progression and death in animals developing spontaneous prostate cancer	Homo sapiens

Organism

Organism	UniProt	Comment	Textmining
Homo sapiens	-	-	-

Source Tissue

Source Tissue	Comment	Organism	Textmining
breast cancer cell	-	Homo sapiens	-
colonic cancer cell	-	Homo sapiens	-
LNCaP cell	androgen-treated and untreated prostate adenocarcinoma cells	Homo sapiens	-
lung cancer cell	-	Homo sapiens	-
prostate gland	-	Homo sapiens	-

Synonyms

Synonyms	Comment	Organism
APAO	-	Homo sapiens
N1-acetyl polyamine oxidase	-	Homo sapiens
PAO	-	Homo sapiens
PAOh1	-	Homo sapiens

General Information

General Information	Comment	Organism
physiological function	polyamine oxidation is a major pathway for reactive oxygen species production in prostate, inhibiting this pathway successfully delays prostate cancer progression	Homo sapiens

Use of this online version of BRENDA is free under the CC BY 4.0 license. See terms of use for full details.

Release 2023.1 (January 2023)